Outcome of Middle East Respiratory Syndrome (MERS) in hematology and oncology patients: A case series in Saudi Arabia.
Infection
Malignancy
Middle East Respiratory Syndrome
Mortality
Journal
Journal of infection and public health
ISSN: 1876-035X
Titre abrégé: J Infect Public Health
Pays: England
ID NLM: 101487384
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
13
10
2020
revised:
08
12
2020
accepted:
16
12
2020
pubmed:
2
3
2021
medline:
31
3
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is associated with a high fatality rate (34%), which is higher in the presence of co-morbidities. The aim of the current study was to assess the clinical course and the outcome in hematological or oncological malignancy cases, diagnosed with MERS-CoV. This is a case series of hematological /oncological cases, diagnosed with MERS-CoV, in a tertiary care setting in 2015. The cases were identified based on the World Health Organization (WHO) MERS-CoV case definition. The demographic, clinical, and outcome data were retrieved from the patients' medical charts and electronic health records. In total, nine hematological or oncological cases were identified, diagnosed with MERS-CoV. The baseline malignant condition was hematological malignancy in seven patients, as well as colon cancer and osteosarcoma in one patient each. Six (67%) patients were male. The median age was 65 years (range 16-80 years). Co-morbidities included chronic kidney disease (n = 3.33%), diabetes mellitus (n = 3.33%), and hypertension (n = 2.22%). The presenting symptoms were shortness of breath (n = 6.66%), fever (n = 5.55%), cough (n = 2.22%), and diarrhea (n = 2.22%). Chest x-rays indicated bilateral infiltrates in 6 patients (66%). The PCR (polymerase chain reaction) test was repeated in six patients to confirm the diagnosis. The mortality rate was 100%, and the median time to death was 26 days (range 15-77 days). MERS-CoV infection in this small cohort of hematology or oncology patients has a 100% mortality rate, regardless of the status of the underlying disease. The confirmation of the diagnosis may require repeated testing. Additional studies are required to verify the findings and to elucidate the disease pathogenesis in cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is associated with a high fatality rate (34%), which is higher in the presence of co-morbidities. The aim of the current study was to assess the clinical course and the outcome in hematological or oncological malignancy cases, diagnosed with MERS-CoV.
METHODS
METHODS
This is a case series of hematological /oncological cases, diagnosed with MERS-CoV, in a tertiary care setting in 2015. The cases were identified based on the World Health Organization (WHO) MERS-CoV case definition. The demographic, clinical, and outcome data were retrieved from the patients' medical charts and electronic health records.
RESULTS
RESULTS
In total, nine hematological or oncological cases were identified, diagnosed with MERS-CoV. The baseline malignant condition was hematological malignancy in seven patients, as well as colon cancer and osteosarcoma in one patient each. Six (67%) patients were male. The median age was 65 years (range 16-80 years). Co-morbidities included chronic kidney disease (n = 3.33%), diabetes mellitus (n = 3.33%), and hypertension (n = 2.22%). The presenting symptoms were shortness of breath (n = 6.66%), fever (n = 5.55%), cough (n = 2.22%), and diarrhea (n = 2.22%). Chest x-rays indicated bilateral infiltrates in 6 patients (66%). The PCR (polymerase chain reaction) test was repeated in six patients to confirm the diagnosis. The mortality rate was 100%, and the median time to death was 26 days (range 15-77 days).
CONCLUSION
CONCLUSIONS
MERS-CoV infection in this small cohort of hematology or oncology patients has a 100% mortality rate, regardless of the status of the underlying disease. The confirmation of the diagnosis may require repeated testing. Additional studies are required to verify the findings and to elucidate the disease pathogenesis in cancer patients.
Identifiants
pubmed: 33647552
pii: S1876-0341(20)30771-1
doi: 10.1016/j.jiph.2020.12.015
pmc: PMC7982909
pii:
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-357Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Trials. 2020 Jan 3;21(1):8
pubmed: 31900204
Crit Care. 2016 May 07;20(1):123
pubmed: 27153800
Infect Dis Clin North Am. 2019 Dec;33(4):891-905
pubmed: 31668197
Clin Infect Dis. 2017 Aug 15;65(4):675-679
pubmed: 28575307
Euro Surveill. 2014 Apr 24;19(16):20781
pubmed: 24786259
BMC Infect Dis. 2018 Dec 29;18(1):707
pubmed: 30594124
N Engl J Med. 2017 Feb 9;376(6):584-594
pubmed: 28177862
Curr Infect Dis Rep. 2013 Aug;15(4):295-8
pubmed: 23793899
Ann Intern Med. 2014 Mar 18;160(6):389-97
pubmed: 24474051
Transbound Emerg Dis. 2017 Apr;64(2):344-353
pubmed: 26256102
BMC Infect Dis. 2017 Sep 11;17(1):615
pubmed: 28893197
Lancet. 2015 Sep 5;386(9997):995-1007
pubmed: 26049252
Emerg Microbes Infect. 2018 Nov 28;7(1):195
pubmed: 30482895
Lancet Infect Dis. 2013 Sep;13(9):745-51
pubmed: 23782859
PLoS One. 2016 Nov 3;11(11):e0165978
pubmed: 27812197
Ann Thorac Med. 2016 Apr-Jun;11(2):128-31
pubmed: 27168861
J Infect Public Health. 2018 Jan - Feb;11(1):9-17
pubmed: 28864360
Vaccine. 2017 Jun 27;35(30):3780-3788
pubmed: 28579232
Emerg Infect Dis. 2015 Nov;21(11):2029-35
pubmed: 26488195
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Infect Chemother. 2016 Jun;48(2):118-26
pubmed: 27433382
Euro Surveill. 2012 Sep 27;17(39):
pubmed: 23041020
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
J Infect Public Health. 2016 May-Jun;9(3):216-9
pubmed: 27106390
J Infect Dis. 2017 Jun 1;215(11):1702-1705
pubmed: 28387845
Mediterr J Hematol Infect Dis. 2020 Sep 01;12(1):e2020070
pubmed: 32952981
N Engl J Med. 2013 Aug 1;369(5):407-16
pubmed: 23782161
Lancet Haematol. 2020 Oct;7(10):e737-e745
pubmed: 32798473
J Infect Chemother. 2017 Nov;23(11):769-773
pubmed: 28545936